The polypeptide may also include additional short sequences at the beginning and end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to bind compete with native IgE for {HEAD ~ the high affinity receptor sites} on {TAIL ~ human cells} 
on
The polypeptide may also include additional short sequences at the beginning and end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to bind compete with native IgE for { HEAD ~ the high affinity receptor sites } on { TAIL ~ human cells }
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD HEAD HEAD REL TAIL TAIL TAIL TAIL TAIL TAIL